mTOR signaling is upregulated in 40–50% of HCCs,17 and this pathway has been studied for the development of molecular targeted therapies for several cancers, including HCC.18 Interestingly, mTOR signaling is regulated by galectin-3,17,18 a well-known binding partner of M2BP protein. Here, LGALS3 is linked to hepatocellular carcinoma.